| Marc D Mecoli, MD | |
|
3333 Burnet Ave, Cincinnati, OH 45229-3026 | |
| (513) 636-7339 | |
| Not Available |
| Full Name | Marc D Mecoli |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 16 Years |
| Location | 3333 Burnet Ave, Cincinnati, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053562298 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 35.123977 (Ohio) | Secondary |
| 207LP3000X | Anesthesiology - Pediatric Anesthesiology | 35.123977 (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Children's Hospital Medical Center | 8426955733 | 473 |
News Archive
Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.
Pending Medicare cuts could mean physician practices would back away from the program, according to a trade group representing these doctor groups, Medscape reports.
The fourth annual Extremity War Injuries Symposium was held in Washington, D.C., last January to bring together military and civilian orthopaedic surgeons, researchers, experts from governmental agencies, and others to discuss challenges faced by U.S. medical personnel working in Iraq and Afghanistan and to discuss ways to synergize resources and improve care for wounded warriors.
GlobalOptions Group, Inc., a leading provider of domestic and international risk management services, affirmed today that James Lee Witt Associates (JLWA), its Crisis Management and Preparedness Services Division, supports the recommendations of a report developed by The Children's Health Fund (CHF) to modify the National Response Framework to include issues addressing case management for children.
› Verified 3 days ago
| Entity Name | Children's Hospital Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609915784 PECOS PAC ID: 8426955733 Enrollment ID: O20031216000035 |
News Archive
Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.
Pending Medicare cuts could mean physician practices would back away from the program, according to a trade group representing these doctor groups, Medscape reports.
The fourth annual Extremity War Injuries Symposium was held in Washington, D.C., last January to bring together military and civilian orthopaedic surgeons, researchers, experts from governmental agencies, and others to discuss challenges faced by U.S. medical personnel working in Iraq and Afghanistan and to discuss ways to synergize resources and improve care for wounded warriors.
GlobalOptions Group, Inc., a leading provider of domestic and international risk management services, affirmed today that James Lee Witt Associates (JLWA), its Crisis Management and Preparedness Services Division, supports the recommendations of a report developed by The Children's Health Fund (CHF) to modify the National Response Framework to include issues addressing case management for children.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marc D Mecoli, MD 3333 Burnet Ave, Cincinnati, OH 45229-3026 Ph: (513) 636-7339 | Marc D Mecoli, MD 3333 Burnet Ave, Cincinnati, OH 45229-3026 Ph: (513) 636-7339 |
News Archive
Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.
Pending Medicare cuts could mean physician practices would back away from the program, according to a trade group representing these doctor groups, Medscape reports.
The fourth annual Extremity War Injuries Symposium was held in Washington, D.C., last January to bring together military and civilian orthopaedic surgeons, researchers, experts from governmental agencies, and others to discuss challenges faced by U.S. medical personnel working in Iraq and Afghanistan and to discuss ways to synergize resources and improve care for wounded warriors.
GlobalOptions Group, Inc., a leading provider of domestic and international risk management services, affirmed today that James Lee Witt Associates (JLWA), its Crisis Management and Preparedness Services Division, supports the recommendations of a report developed by The Children's Health Fund (CHF) to modify the National Response Framework to include issues addressing case management for children.
› Verified 3 days ago
Alexander Topala, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 234 Goodman St, Mail Location 0796, Cincinnati, OH 45219 Phone: 513-584-1000 | |
Eli Cianciolo, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4805 Montgomery Rd, Suite 210, Cincinnati, OH 45212 Phone: 513-791-6400 Fax: 513-791-5306 | |
Angel Joshua Pagan, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 234 Goodman St, Cincinnati, OH 45219 Phone: 513-558-6356 | |
Dave Wright, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2139 Auburn Ave, Cincinnati, OH 45219 Phone: 513-585-2422 Fax: 513-585-3245 | |
Robert S Jacob, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2139 Auburn Ave, Cincinnati, OH 45219 Phone: 513-672-3309 Fax: 513-672-3323 | |
Mr. Kun Lee, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 4777 E Galbraith Rd, Cincinnati, OH 45236 Phone: 513-686-3000 | |
Nalini Tandon, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 7500 State Rd, Anethesia Intensive Care Consultants Inc, Cincinnati, OH 45255 Phone: 859-341-7246 Fax: 859-341-7867 |